Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126748
Filing Date
2024-11-14
Accepted
2024-11-14 08:03:11
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q snse-20240930.htm   iXBRL 10-Q 1917671
2 EX-10.1 snse-ex10_1.htm EX-10.1 153707
3 EX-31.1 snse-ex31_1.htm EX-31.1 15652
4 EX-31.2 snse-ex31_2.htm EX-31.2 16834
5 EX-32.1 snse-ex32_1.htm EX-32.1 9973
  Complete submission text file 0000950170-24-126748.txt   7618822

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT snse-20240930.xsd EX-101.SCH 1188608
76 EXTRACTED XBRL INSTANCE DOCUMENT snse-20240930_htm.xml XML 988414
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39980 | Film No.: 241457308
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)